Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Abbott Labs

Automatic Data Processing

Aflac

A. O. Smith

Air Products and Chemicals

Franklin Resources

Caterpillar

Cincinnati Financial

Colgate-Palmolive

Clorox

Cintas Corp

Chevron

Expeditors International of Washington

General Dynamics

Genuine Parts

W.W. Grainger

Hormel Foods

Illinois Tool Works

Johnson & Johnson

Kimberly-Clark

Coca-Cola

New Linde PLC

Lowe's

I propose leveraging the stock selection criteria from the underlying index of SCHD to build a portfolio with a subset of Dividend Aristocrats. I am tracking two portfolios built using this process and comparing the results to NOBL and SCHD.

Selecting Dividend Aristocrats Using SCHD Methodology - Mounting A Comeback

Agilent Technologies

Agree Realty

Ameren

Federal Agricultural

Albemarle

Allstate

Allegion

Amphenol

Alexandria Real Estate Equities

Atrion

Broadcom

Axis Capital

Bank of America

Brookfield Asset Management

BancFirst

Baxter

Becton, Dickinson and Co.

BWX Technologies

Cadence Bank

Crown Castle International

C.H. Robinson Worldwide

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

Dividend Champion, Contender, And Challenger Highlights: Week Of March 26

Duke Energy

General Mills

Cardinal Health's healthcare operations make it resilient as it generates billions in free cash flow. General Mills' strong brands have enabled the business to pass on higher prices to consumers.

Don't Wait for Your Dividends. Here's How You Can Collect Cash Every Month.

Adobe

Tapestry

The vast majority of Adobe's revenue comes from subscriptions, making this a fairly stable business to invest in right now. Tapestry's high-end apparel and accessories cater to affluent customers who may be less affected by inflation.

3 Inflation-Resistant Businesses That Recently Raised Guidance

AmerisourceBergen

Valero Energy

Andersons

BioNTech SE

Offerpad Solutions

Performance Food Group

While time in the market generally beats out timing the market, it's understandable that some investors may want to hold off on looking for stocks to buy. After all, equities continue to digest the sudden failure of a handful of financial institutions.

7 Stocks Set to Soar When the Market Recovers

NEWPORT NEWS, Va. , March 16, 2023 /PRNewswire/ -- Swisslog, a leading provider of best-in-class warehouse automation and software, has announced that Cardinal Health (NYSE: CAH) will install a Swisslog Automation Solution within its new at-Home Solutions distribution center in Grove City, Ohio.

Swisslog's robotic fulfillment system and software to support new Cardinal Health at-Home Solutions distribution center

Medtronic

Roper Technologies

West Pharmaceutical Services

While it is not the only factor to consider, the annual dividend can solidify whether a stock will benefit you financially. And among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.

Healthcare Stocks With at Least 30 Years of Dividend Increases

At this stage, it will be prudent to stay with safe stocks.Five such stocks are: CAH, CINF, CLX, KO and GIS.

5 Safe Stocks to Buy as SVB Collapse Shakes Wall Street

Cardinal Health is a leader in its industry and has had another stellar quarterly performance with revenues increasing 13%. A part of a growing industry, the company has both a strong financial ground to stand on and plenty of industry tailwinds.

Cardinal Health Continues Meeting Expectations

Cardinal (CAH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -10.82% in 4 Weeks, Here's Why the Trend Might Reverse for Cardinal (CAH)

Amcor Plc

Essex Property Trust

Federal Realty Investment Trust

Realty Income Corp

Sysco

T. Rowe Price Group

V.F.

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." --Kiplinger.com/Investing. 67 Aristocrats screened as of March 8, 2023, represented all eleven Morningstar Sectors. Broker estimated top ten net gains ranged 16.32%-32.64% topped by WBA & VFC.

The 4 Dividend Aristocrat Buys For March

Cardinal Health's (CAH) latest partnership is expected to improve patients' healthcare journey by offering a more integrated experience that connects all sites of care.

Cardinal Health's (CAH) New Tie-Up to Boost Patient Outcomes

Signify Health

DUBLIN, Ohio , March 6, 2023 /PRNewswire/ -- Cardinal Health  (NYSE:CAH) today announced its collaboration with Signify Health (NYSE:SGFY) to offer in-home clinical and medication management services through its Outcomes™ business. This collaboration will help reduce costs and eliminate gaps in care for more than 2.3 million members nationwide to support their treatment journey from prescription to pharmacy to home.

Cardinal Health's Outcomes™ collaborates with Signify Health to offer in-home medication therapy management

PepsiCo

One of the best ways for investors to save for the future and retirement is to consistently invest money into tax-sheltered vehicles, whether it be a 401(k) plan or self-directed individual retirement account (IRA).

7 ‘Strong Buy' 2023 Dividend Aristocrats to Buy Now and Hold Forever in Your IRA

News for Cardinal Health Stock (CAH)